291 related articles for article (PubMed ID: 34386813)
21. Screening and identification of angiogenesis-related genes as potential novel prognostic biomarkers of hepatocellular carcinoma through bioinformatics analysis.
Zhen Z; Shen Z; Hu Y; Sun P
Aging (Albany NY); 2021 Jul; 13(13):17707-17733. PubMed ID: 34252885
[TBL] [Abstract][Full Text] [Related]
22. A Predictive Model Based on the FBXO Family Reveals the Significance of Cyclin F in Hepatocellular Carcinoma.
Gao D; Li S; Guo H; Liu X; Liu Z; Li L; Bao L; Dang X
Front Biosci (Landmark Ed); 2024 May; 29(5):202. PubMed ID: 38812312
[TBL] [Abstract][Full Text] [Related]
23. Multi-omics data identified TP53 and LRP1B as key regulatory gene related to immune phenotypes via EPCAM in HCC.
Shi L; Cao J; Lei X; Shi Y; Wu L
Cancer Med; 2022 May; 11(10):2145-2158. PubMed ID: 35150083
[TBL] [Abstract][Full Text] [Related]
24. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma.
Wang Z; Zhu J; Liu Y; Liu C; Wang W; Chen F; Ma L
J Transl Med; 2020 Feb; 18(1):67. PubMed ID: 32046766
[TBL] [Abstract][Full Text] [Related]
25. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis.
Xiao H; Wang B; Xiong HX; Guan JF; Wang J; Tan T; Lin K; Zou SB; Hu ZG; Wang K
J Cell Physiol; 2021 Apr; 236(4):2572-2591. PubMed ID: 32853412
[TBL] [Abstract][Full Text] [Related]
26. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
27. Tumor-adjacent tissue co-expression profile analysis reveals pro-oncogenic ribosomal gene signature for prognosis of resectable hepatocellular carcinoma.
Grinchuk OV; Yenamandra SP; Iyer R; Singh M; Lee HK; Lim KH; Chow PK; Kuznetsov VA
Mol Oncol; 2018 Jan; 12(1):89-113. PubMed ID: 29117471
[TBL] [Abstract][Full Text] [Related]
28. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.
Li Y; He X; Zhang X; Xu Y; Wu Y; Xu X
Life Sci; 2021 Jan; 265():118799. PubMed ID: 33220285
[TBL] [Abstract][Full Text] [Related]
29. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma.
Sun XY; Yu SZ; Zhang HP; Li J; Guo WZ; Zhang SJ
Cancer Med; 2020 Apr; 9(8):2868-2878. PubMed ID: 32068352
[TBL] [Abstract][Full Text] [Related]
30. Identification and validation of EPHX2 as a prognostic biomarker in hepatocellular carcinoma.
Zhan K; Bai Y; Liao S; Chen H; Kuang L; Luo Q; Lv L; Qiu L; Mei Z
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278494
[TBL] [Abstract][Full Text] [Related]
31. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
32. Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.
Huo J; Wu L; Zang Y
J Cell Mol Med; 2021 Jan; 25(2):1151-1165. PubMed ID: 33300278
[TBL] [Abstract][Full Text] [Related]
33. Identification of a thirteen-gene signature predicting overall survival for hepatocellular carcinoma.
Zhou X; Liu C; Zeng H; Wu D; Liu L
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33835133
[TBL] [Abstract][Full Text] [Related]
34. LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment.
Cheng Y; Tang R; Li X; Wang B; Cheng Y; Xiao S; Sun P; Yu W; Li C; Lin X; Zhu Y
J Hepatocell Carcinoma; 2022; 9():203-220. PubMed ID: 35345553
[TBL] [Abstract][Full Text] [Related]
35. Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5.
Xu R; Lin L; Zhang B; Wang J; Zhao F; Liu X; Li Y; Li Y
BMC Cancer; 2021 Jun; 21(1):687. PubMed ID: 34112092
[TBL] [Abstract][Full Text] [Related]
36. Exploring the Prognostic Value, Immune Implication and Biological Function of
Huang Y; Huang S; Ma L; Wang Y; Wang X; Xiao L; Qin W; Li L; Yuan X
Front Immunol; 2021; 12():723293. PubMed ID: 34899687
[TBL] [Abstract][Full Text] [Related]
37. Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.
Pan B; Cheng J; Tan W; Wu X; Fan Q; Fan L; Jiang M; Yu R; Cheng X; Deng Y
Aging (Albany NY); 2024 May; 16(9):8171-8197. PubMed ID: 38738999
[TBL] [Abstract][Full Text] [Related]
38. KIF18B as a regulator in tumor microenvironment accelerates tumor progression and triggers poor outcome in hepatocellular carcinoma.
Qiu MJ; Zhang L; Chen YB; Zhu LS; Zhang B; Li QT; Yang SL; Xiong ZF
Int J Biochem Cell Biol; 2021 Aug; 137():106037. PubMed ID: 34217812
[TBL] [Abstract][Full Text] [Related]
39. Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.
Xu Q; Wang Y; Huang W
Int Immunopharmacol; 2021 Mar; 92():107333. PubMed ID: 33486322
[TBL] [Abstract][Full Text] [Related]
40. SLC25A19 is a novel prognostic biomarker related to immune invasion and ferroptosis in HCC.
Liu S; Zhang P; Wu Y; Zhou H; Wu H; Jin Y; Wu D; Wu G
Int Immunopharmacol; 2024 Jul; 136():112367. PubMed ID: 38823177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
